Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.35 |
| ▸ | SELL | P14151 | 2/20 | 0.34 |
| ▸ | SELP | P16109 | 2/20 | 0.34 |
| ▸ | SELE | P16581 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24265817 | 0.87 | SERPINE1 (0.38) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL19477894 | 0.84 | RAB9A (0.37) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL7497047 | 0.76 | NPC1 (0.43) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL24265373 | 0.73 | SELL (0.37) | HPGDMAPK1HTTALOX15SERPINE1 | |
| SCHEMBL20849682 | 0.73 | MAPK1 (0.46) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL2986688 | 0.73 | TNKS2 (0.52) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL6351058 | 0.71 | NPC1 (0.72) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL19857034 | 0.71 | HDAC3 (0.55) | MAPK1SELLSELPSELE | |
| SCHEMBL6356508 | 0.70 | PTGS2 (0.65) | NPC1HPGDMAPK1HTTRAB9A | |
| SCHEMBL31672996 | 0.69 | MAPT (0.55) | MAPK1SELLSELPSELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220054516-A1 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054516-A1 | COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ACE, ACE2, FURIN | NPC1 39/4885HPGD 1625/4885MAPK1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.